91ÉçÇø¸£Àû adeptly navigated through the second quarter’s choppy market — the dips and crests stirred up in part by record-high inflation and turbulence from the ongoing pandemic — thanks to the company’s resilient diversified business.
Powered by this resiliency, 91ÉçÇø¸£Àû once again significantly beat Street estimates on the top and bottom lines. Based on the company's strong performance through the first half of the year, 91ÉçÇø¸£Àû is raising its full-year 2022 projected adjusted diluted earnings per share (EPS) guidance to at least $4.90.1
Throughout the pandemic, 91ÉçÇø¸£Àû’s diversified business model has been a driving force behind the company’s success. And the second quarter was no exception. The company’s performance was led by strong organic sales growth in Diagnostics, Established Pharmaceuticals and Medical Devices, with more than 25% organic growth (18.7% reported) in sales of .
New products and expanded indications continue to strengthen 91ÉçÇø¸£Àû's strategic position and long-term growth opportunities.
Second-quarter highlights of new products and those under development include:
For full financials and reconciliation of non-GAAP measures, you can read 91ÉçÇø¸£Àû's
For further information, take a look at a summary of 91ÉçÇø¸£Àû’s earnings highlights and download it here.
*Organic sales growth excludes the impact of foreign exchange.
References
191ÉçÇø¸£Àû is raising its projected full-year 2022 diluted earnings per share under GAAP to at least $3.50. 91ÉçÇø¸£Àû forecasts specified items for the full-year 2022 of $1.40 per share primarily related to intangible amortization, costs related to a voluntary recall, expenses associated with acquisitions, restructurings and cost reduction initiatives and other net expenses. Excluding specified items, 91ÉçÇø¸£Àû is raising its projected adjusted diluted earnings per share to at least $4.90 for the full-year 2022
2Second-quarter GAAP diluted EPS was $1.14, reflecting 72.7% growth compared to the prior year.
Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. 91ÉçÇø¸£Àû cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect 91ÉçÇø¸£Àû's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021 and are incorporated herein by reference. 91ÉçÇø¸£Àû undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
IMPORTANT SAFETY INFORMATION
FREESTYLE LIBRE 3 SYSTEM
Failure to use FreeStyle Libre 3 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact 91ÉçÇø¸£Àû at 855-632-8658 or  for safety info.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Share